Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy.

Accept / Decline

Ferring Canada

Navigation

Follow Us

Newsroom

Tuesday, 25 November 2014

New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists
Monday, 10 November 2014

Ferring Pharmaceuticals (Ferring) has appointed Hardus van Vuuren as Business Unit Director, Reproductive Health, in its Canadian operation
Friday, 01 August 2014

Ferring Canada appoints four new Managers
Tuesday, 24 June 2014

Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment
Monday, 19 May 2014

Ferring Global launches Guts4life, an interactive online resource for people with inflammatory bowel disease
Friday, 09 May 2014

New study suggests desmopressin melt improves sleep patterns and psychological functioning of bedwetting children
Tuesday, 06 May 2014

Ferring Canada supports disease awareness on Inflammatory Bowel Disease (IBD)
Friday, 04 April 2014

Ferring, MSD and WHO work to prevent excessive bleeding after childbirth
Tuesday, 18 March 2014

Ferring Research Institute is pleased to announce the launch of our new Ferring Innovation Grants program
Friday, 14 February 2014

Ferring Canada Transfers the Divigel® Marketing Rights to Teva Canada Innovation
Tuesday, 11 February 2014

New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists.
Tuesday, 11 February 2014

A two page interview with Michel Pettigrew, President of the Executive Board & Chief Operating Officer, Ferring Group, was published in the February 2014 edition of PME (Pharmaceutical Market Europe) magazine.
Tuesday, 11 February 2014

Ferring Canada received a Research Partner Recognition Award during the Canadian Digestive Disease Week
Thursday, 30 January 2014

Ferring Canada collabores with the Canadian Digestive Health Foundation to introduce an educational video on bowel preparation
Monday, 06 January 2014

Ferring Pharmaceuticals (Ferring) has appointed Dr. Teodor Burtea as Medical Director of its Canadian Operation

Canada

Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1
Canada

Tel: +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692

Global Locator

Corporate Global Locator

Ferring Pharmaceuticals is a research-driven biopharmaceutical company dedicated to researching, developing and marketing innovative treatments in a number of key therapeutic areas including reproductive health, urology, and gastroenterology. Founded in 1950, Ferring now operates from more than 55 countries and employs more than 4500 people throughout the world, while treatments are available in more than 100 countries. At its seven R&D centres, Ferring scientists strive to improve existing therapies and to create inventive new treatments that address unmet medical needs and help people of all ages live better. And, in every aspect of our business, we follow the Ferring Philosophy: “People Come First at Ferring”. It’s more than just five simple words. To us, it is a guiding principle that inspires everything we do - from our business practices to our relationships with patients and physicians.

Photo of Ferring Headquarters, Saint-Prex, Switzerland (www.ferring.com)

This Canadian website provides general information about Ferring Canada. For information about Ferring Global or its products in some other specific country, please go to ferring.com

FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise.
©2016 Ferring B.V.